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ABSTRACT
Breast malignancies, apart from skin cancer, are the leading cause of cancer 
from cancer among the female population. Unlike the high prevalence of 
primary mammary malignancies, metastases to the breast are uncommon, 
and account for only 0.2-2.7% of all malignancies affecting this organ. We 
report the case of a 35-year-old woman who sought medical care because of 
a breast lump. A mammogram suggested a breast tumor, which was biopsied. 
The histopathological workup resulted in the diagnosis of a metastasis from 
a medullary thyroid cancer. The authors review the most useful clinical, 
radiological, histological, and immunohistochemical features concerning 
extramammary malignancy to the breast.
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CASE REPORT
A 35-year-old female patient sought medical 
care complaining of a palpable nodule in the left 
breast. The mammogram revealed clustered 
calcifications in the left upper quadrant (BIRADS 3). 
Complementary ultrasound showed a hypoechoic 
lesion, without acoustic shadow. The patient was 
submitted to a core needle biopsy and 12 tissue 
samples were obtained. The histological examination 
revealed a well-differentiated carcinoma infiltrating 
the mammary parenchyma, with peripheral 
microcalcifications, but an absence of the in 
situ component (Figure 1). The main diagnostic 
hypothesis was invasive breast carcinoma nuclear 
and histological (Nottingham) grade 2.
The complementary immunohistochemical 
research revealed positivity for E-cadherin and 
negativity for hormone receptors (estrogen and 
progesterone), as well as for oncogene HER2 
(c-ERB2), besides a low proliferation index identified 
by less than 5% of positivity for Ki-67 (Figure 2).
The discrepancy between histological 
findings of invasive carcinoma and a triple negative 
phenotype, besides the low proliferative index, evoked 
an additional clinical workup. According to a clinical 
history, obtained in a second opportunity, the patient 
had previously had a total thyroidectomy for the 
treatment of a medullary thyroid cancer 5 years ago.
54
Autopsy and Case Reports 2014; 4(1): 53-57 Martins Filho SN, Giannotti MA, Siqueira SAC.
In the light of these histological findings 
and additional clinical information, a new 
immunohistochemical panel was tested, which 
showed positive for chromogranin and calcitonin 
(Figure 3). Based on this new data, the diagnosis 
could be made of metastatic medullary thyroid 
cancer in the mammary parenchyma.
In the course of the disease, the patient 
also presented suspicious metastatic lesions in 
the proximal tibia, sacrum e lumbar spine, mild 
enlargement of the mediastinal and axillary lymph 
nodes besides pulmonary and hepatic nodules. 
Biopsy of the tibia confirmed a metastatic lesion of 
the medullary thyroid cancer.
Figure 1 – Photomicrography of the biopsied specimen (mammary tissue). A – Well-differentiated carcinoma 
infiltrating the mammary parenchyma (HE, 100X). B – In detail: note the cellular pattern arrangement and the 
scarcity of mitotic figures (HE, 400X).
Figure 2 – Photomicrography of the biopsied specimen (mammary tissue). Immunohistochemical preliminary 
workup. A – Negative for the nuclear estrogenic receptor (200X). B – Negative for the nuclear progesterone 
receptor (400X). C – Negative for cEBR (HER2) (400X). D – Proliferative index below 5% (Ki67) (400X).
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is slightly higher in post-mortem studies, where this 
finding reaches 7%.7,12
Hematologic malignancies especially 
diffuse large-cell lymphomas, represent the most 
common source of breast metastatic disease. 
The differentiation between primary lymphoma 
of the breast or secondary involvement of the 
mammary parenchyma follows clinical criteria. 
Other hematological malignancies also related to 
secondary involvement of the breast include low 
grade lymphomas (follicular and lymphocytic), 
leukemia, and exceptionally, multiple myeloma.7,13,14
The incidence of metastatic breast 
involvement from solid tumors is slightly smaller. 
However, the morphologic similarities with primary 
breast tumors impose a tough diagnostic challenge, 
especially in the absence of clinical information and/
or oncologic medical history. Gastric and pulmonary 
carcinomas are the solid tumors that are more likely 
to be responsible for breast metastatic involvement, 
followed by malignant melanoma, carcinoid tumors, 
carcinoma of the ovary (mainly the serous papillary 
carcinoma), liver, kidney, prostate, thyroid, and 
sarcomas.7-11,15,16
The previous or current diagnosis of 
malignancy of any primary site, other than the 
breast, consists the cornerstone for the diagnosis 
of secondary involvement of the mammary 
parenchyma. The suspicion is reinforced when 
multiple other sites are also involved. Clinical 
features that aid the diagnosis of breast metastatic 
involvement include a fast-growing painless breast 
lump, upper outer quadrant involvement and the the 
absence of peau d’orange or nipple retraction. The 
diagnosis of the primary tumor and the metastasis 
DISCUSSION
Medullary thyroid cancer is an uncommon 
malignant neoplasia, accounting for less than 10% 
of all cancers of the thyroid. Local invasion is the 
most common behavior followed by metastatic 
dissemination through the cervical and mediastinal 
lymphatic chains. Generalized disease usually 
occurs late in the course of the illness and 
predominantly involves the liver, bones, central 
nervous system, and adrenal glands.1-4
To date, less than 10 cases of medullary 
carcinoma of the thyroid metastatic to the breast 
have been reported. The first reports date from 2007, 
but in all of those cases the thyroid neoplasm was 
previously known, even though the hypothesis of 
primary breast malignant disease was considered, 
which was probably due to the marked difference 
in the incidence of these two neoplasms. In all of 
those cases, the combined analysis, including 
clinical findings, radiologic examination, histologic 
and immunohistochemical studies, enabled the 
appropriate diagnosis.3-5
The Brazilian National Institute of Cancer 
(INCA) estimates that in 2014 there will be 57,120 
new cases of breast cancer among females, but only 
only 8,050 thyroid malignancies. This high incidence 
of malignant breast cancer does not include breast 
metastatic involvement occurring independently of 
the primary site.6
The prevalence of mammary metastatic 
involvement (regardless of the primary site) is 
infrequent, varying between 0.2 and 2.7% of all 
malignant tumors affecting the breast.7-11 This rate 
Figure 3 – Photomicrography of the biopsied specimen (mammary tissue). Complementary 
immunohistochemical workup. A – Chromogranin positive. B – Calcitonin positive.
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The case reported herein represents the 
fundamental clinicopathological correlation in the 
diagnostic process of extramammary malignancies 
to the breast. The more clinical data that is given to 
the pathologist the more accurate and less expensive 
the final diagnosis will be. The lack of clinical data 
available to the pathologist is not uncommon, which 
challenges him to reach an accurate diagnosis 
without the complete clinical history.
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